Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from N4 Pharma ( (GB:N4P) ).
N4 Pharma has announced promising in vitro results for its lead program, N4 101, an oral anti-inflammatory product for Inflammatory Bowel Disease (IBD). The results demonstrated that their Nuvec® delivery platform effectively enhances the delivery and efficacy of RNA therapeutics, showing competitive advantages over other delivery methods. This progress supports the potential of Nuvec® to secure commercial partnerships and reflects a positive step towards further pre-clinical and eventual clinical trials.
More about N4 Pharma
N4 Pharma is a pre-clinical biotech firm focusing on the development of Nuvec®, a proprietary gene delivery system aimed at advancing therapies for cancer and other diseases. The company is leveraging Nuvec®’s advantages in RNA gene delivery, such as the ability to deliver multiple RNA therapies in a single particle, oral delivery protection, and stability, to establish significant licensing agreements with gene therapy partners.
YTD Price Performance: -35.29%
Average Trading Volume: 1,452,286
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £5.97M
See more insights into N4P stock on TipRanks’ Stock Analysis page.
